At a glance
ClinicalIndex Comparison RecordN/ACompleted· 139 enrolled
Drug / intervention
reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction in Patients Undergoing High-dose Antipsychotic Therapy
In Brief
A clinical study evaluating reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine for Schizophrenia Relapse. Completed, enrolled 139 participants.
Detailed Summary
To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia Relapse
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
Primary CompletionJan 2017
First PostedJan 2017
TodayJul 2026
First PostedJan 13, 2017
Enrollment StartApr 1, 2011
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 9.5 years ago
Interventions
reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazinedrug